Waldencast plc is acquiring Novaestiq Corp. to enhance its Obagi Medical brand with innovative injectable hyaluronic acid gels, targeting the growing U.S. skincare market.

Target Company Overview

Novaestiq Corp. (Novaestiq) is a prominent player in the skincare industry, recognized for its innovative joint-venture with Croma-Pharma GmbH, focusing on developing a range of injectable hyaluronic acid gels tailored for the United States market. With an impressive portfolio that includes products like Saypha® ChIQ™ and Saypha® MagIQ™, Novaestiq is strategically positioned to enhance its market presence through the acquisition by Waldencast plc.

With over 35 years of expertise, Obagi Medical serves as the strategic brand under which these new products will be marketed. Obagi is renowned for its evidence-based approach to skincare, integrating robust dermatological research with aesthetic procedures, thereby enhancing skin health and rejuvenation.

Industry Overview

The skincare industry in the United States is experiencing substantial growth, driven by increasing consumer demand for high-quality products and advanced aesthetic trea